Winning ENTA Stock Forecast: Enanta Pharmaceuticals shows constant promising R&D results
Winning ENTA Stock Forecast: Enanta Pharmaceuticals shows constant promising R&D results
Enanta also has three clinical stage internally invented and wholly owned programs in areas of high unmet need namely NASH, PBC and RSV. And I would note, all three of these development programs now have fast track designation.
- Jay Luly, President and CEO
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), incorporated on July 25, 1995, is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development